Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study

We performed a prospective observational study of chronic myeloid leukemia (CML) patients after anti-SARS-CoV-2 BNT162b2 vaccination (VC). In total, 32 CML patients with tyrosine kinase inhibitor (TKI) therapy, 10 CML patients with treatment-free remission, and 16 healthy subjects participated in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Katagiri, Seiichiro, Akahane, Daigo, Otsuki, Shunsuke, Suto, Arisa, Yamada, Akiko, Suguro, Tamiko, Asano, Michiyo, Yoshizawa, Seiichiro, Tanaka, Yuko, Furuya, Nahoko, Fujimoto, Hiroaki, Okabe, Seiichi, Gotoh, Moritaka, Ito, Yoshikazu, Gotoh, Akihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501552/
https://www.ncbi.nlm.nih.gov/pubmed/36146482
http://dx.doi.org/10.3390/vaccines10091404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501552/
https://www.ncbi.nlm.nih.gov/pubmed/36146482
http://dx.doi.org/10.3390/vaccines10091404

Ejemplares similares